Q&A: New Rules for Clinical Trials conducted in the EU
Recommendation

28/29 April 2026
From QbD to Process Validation
Following the positive vote in Parliament for the new Clinical Trial Regulation, the EU Commission has published a set of Q&As on clinical trials.
Here it is also discussed why the current legislation is being replaced and the main changes are summarised:
- The new authorisation procedure
- The simplified reporting procedures
- More rights for the Commission to conduct controls
In the new regulation, the concept of tacit agreement in the assessment phase of an application will be extended. According to the Q&A, this was needed "to avoid bottlenecks and delays in the procedure".
Related GMP News
16.04.2026EMA Guidance on Conducting Clinical Trials during Public Health Emergencies
16.04.2026EMA accelerates Development of Medicines
16.04.2026What are the GMP Requirements for Drug Development?
26.03.2026FDA Guidance on Statistical Methods for Clinical Trials
26.03.2026Final ICH M11 CeSHarP Guideline
24.02.2026Good AI Practice in Drug Development


